Cullinan Therapeutics, Inc. (CGEM)
Nasdaq: CGEM · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2020
Who owns Cullinan Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Bvf Partners L P/il holds 9.99% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
12
report now, of 24 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Bvf Partners L P/il
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 9.99% in May 15, 2026
Lynx1 Capital Management LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · 14.5% in Oct 10, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G · filed Aug 14, 2026 · COMMON STOCK
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Kynam Capital Management, LP
SCHEDULE 13G · filed Mar 4, 2026 · Common Stock, par value $0.0001 per share
Deerfield Mgmt, L.P.
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock · reported falling below 5%
Franklin Resources, Inc.
SCHEDULE 13G/A · filed Oct 31, 2024 · Common Stock, par value $0.0001 per share · reported falling below 5%
Kenneth Griffin
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share (the "Shares") · reported falling below 5%, from 5.1% in Aug 6, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.58% in Jan 30, 2026
What CGEM reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Cullinan
An entity · legal entity, related party · owns, named in the 10-K filed Mar 10, 2026
Cullinan M I C A Corp
An entity · legal entity · owns, named in the 10-K filed Mar 10, 2026
4 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 10, 2026.
Insider tradesForm 4
29sales
0purchases
17sales on a scheduled plan
5people selling
$2.6Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 44 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | 19 | $1.7M | 17 | 0 | $0 |
| Ahmed Nadim | President and CEO | 3 | $500,000 | 0 | 0 | $0 |
| Jones Jeffrey Alan | Chief Medical Officer | 3 | $200,000 | 0 | 0 | $0 |
| Fenton Mary Kay | Chief Financial Officer | 1 | $100,000 | 0 | 0 | $0 |
| Sumer Jacquelyn L | Chief Legal Officer | 3 | $100,000 | 0 | 0 | $0 |